This is an investigational study. Bevacizumab and paclitaxel are FDA approved and commercially available for the treatment of several types of cancer. This drug combination is approved for the treatment of epithelial ovarian, primary peritoneal, and fallopian tube cancer. Emactuzumab is not FDA approved or commercially available. The addition of emactuzumab to the combination of bevacizumab and paclitaxel is investigational and is currently being used for research purposes only. The doctor can explain how the study drugs are designed to work.